Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 8-Week, Multicenter, Open-Label, Observational Study of the Efficacy of Quetiapine Fumarate (SEROQUEL) Immediate-Release Tablets in Adult Patients With Bipolar Depression

NCT00523601 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00523601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00523601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 8-Week, Multicenter, Open-Label, Observational Study of the Efficacy of Quetiapine Fumarate (SEROQUEL) Immediate-Release Tablets in Adult Patients With Bipolar Depression
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
June 30, 2007
Completion date
December 31, 2007
Enrollment
2,000 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar depression